Skip to main content
SpringerLink
Log in

Clinical Results of If Current Inhibition by Ivabradine

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Heart rate reduction is a well accepted and effective approach for the prevention of angina pectoris. Ivabradine is the first selective and specific inhibitor of the If current and provides pure heart rate reduction without altering myocardial contractility. Clinical evidence of the antianginal and anti-ischaemic efficacy and tolerability of ivabradine comes from the largest clinical development programme that has ever been performed in stable angina pectoris, involving more than 5000 patients. Ivabradine at the dosages of 5 or 7.5mg twice daily is as effective as reference antianginal approaches such as β-adrenoceptor antagonists and calcium channel antagonists. The clinical efficacy and safety of ivabradine has also been confirmed in a 1-year follow-up study. Ivabradine is well tolerated and free from the most commonly observed adverse effects of currently prescribed antianginal drugs. Visual symptoms can occur in a minority of patients treated with ivabradine and are not associated with structural ocular changes. The ongoing clinical development programme with the two major morbidity-mortality studies, BEAUTIFUL and SHIfT, has the potential to greatly extend the use of ivabradine in patients with coronary artery disease as well as in those with heart failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Elveback LR, Connolly DC, Melton LJ. Coronary heart disease in residents of Rochester, Minnesota: incidence 1950 through 1982. Mayo Clin Proc 1986; 61: 896–900

    Article  PubMed  CAS  Google Scholar 

  2. European Society of Cardiology. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18: 394–413

    Article  Google Scholar 

  3. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation 1999; 99: 2829–48

    PubMed  CAS  Google Scholar 

  4. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity: circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 1993; 88: 92–100

    CAS  Google Scholar 

  5. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967–74

    Article  PubMed  Google Scholar 

  6. Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352: 1951–8

    Article  PubMed  CAS  Google Scholar 

  7. Cucherat M. Relationship between heart rate lowering and benefits on cardiac and sudden death observed with beta-blockers in post MI patients: a meta-regression of randomized clinical trials [abstract 3633]. Eur Heart J 2006; 27 Suppl.: 590

    Google Scholar 

  8. Palatini P, Thijs L, Staessen JA, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313–21

    Article  PubMed  Google Scholar 

  9. Braunwald E. Heart disease: a textbook of cardiovascular medicine. 3rd ed. Philadelphia (PA): W.B. Saunders, 1988: 1330

    Google Scholar 

  10. Frishman WH, Sica DA. Calcium channel blockers. In: Frish-man WH, Sonnenblick EH, Sica DA, editors. Cardiovascular pharmacotherapies. 2nd ed. New York: McGraw-Hill, 2003: 105–30

    Google Scholar 

  11. DiFrancesco D. Characterization of single pacemaker channels in cardiac sino-atrial node cells. Nature 1986; 324: 470–3

    Article  PubMed  CAS  Google Scholar 

  12. DiFrancesco D. The contribution of the ‘pacemaker’ current (If) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J Physiol 1991; 34: 23–40

    Google Scholar 

  13. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo-controlled trial. Circulation 2003; 107: 817–23

    Article  PubMed  Google Scholar 

  14. Savelieva I, Borer JS, Camm J. Low Incidence of significant bradycardia during therapy with an If current inhibitor ivabradine: heart rate reduction depends on baseline heart rate [abstract 1007-195]. J Am Coll Cardiol 2007; 49 (3 Suppl. A): 9

    Google Scholar 

  15. Tardif JC, Ford I, Tendera M, et al., for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529–36

    Article  PubMed  CAS  Google Scholar 

  16. Simon L, Ghaleh B, Puybasset L, et al. Coronary and haemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659–66

    PubMed  CAS  Google Scholar 

  17. Ruzyllo W, Tendera M, Ford I, et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007; 67: 393–405

    Article  PubMed  CAS  Google Scholar 

  18. Lopez-Bescos L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology 2007 Sep 21; 108(4): 387–96

    Article  PubMed  CAS  Google Scholar 

  19. Savelieva I, Camm AJ. Absence of direct effects of the If current blocker ivabradine on ventricular repolarization: analysis based on a population heart rate correction formula [abstract no. 1023-272]. J Am Coll Cardiol 2005; 45 Suppl.: 95A

    Google Scholar 

  20. Beere PA, Glagov S, Zarina CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180–2

    Article  PubMed  CAS  Google Scholar 

  21. Perski A, Harnstein A, Lindvall K, et al. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am Heart J 1988; 116: 1369–73

    Article  PubMed  CAS  Google Scholar 

  22. Sutton Tyrrell K, Alcon HG, Wolfson Jr SK, et al. Predictors of carotid stenosis in older adults with and without isolated systolic hypertension. Stroke 1993; 24: 355–61

    Article  PubMed  CAS  Google Scholar 

  23. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477–82

    Article  PubMed  CAS  Google Scholar 

  24. Benetos A, Rudnichi A, Homas F, et al. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 1999; 33: 44–52

    Article  PubMed  CAS  Google Scholar 

  25. Menotti A, Mulder I, Nissinen A, et al. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: the FINE study (Finland, Italy, Netherlands, Elderly). J Clin Epidemiol 2001; 54: 680–6

    Article  PubMed  CAS  Google Scholar 

  26. Kjekshus J. Importance of heart rate in determining β-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-9F

    Article  Google Scholar 

  27. Kjekshus J, Gukkestad L. Heart rate as therapeutic target in heart failure. Eur Heart J 1999; 1 Suppl. H: H64–9

    Google Scholar 

  28. Thackray SD, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006; 152(4): 713.e9-13

    Article  PubMed  CAS  Google Scholar 

  29. Fox K, Ferrari R, Tendera M, et al., on behalf of the BEAUTIfUL Steering Committee. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIfUL) study. Am Heart J 2006; 152: 860–6

    Article  PubMed  CAS  Google Scholar 

  30. Jondeau G, Korewicki J, Vasiliauskns D. Effect of ivabradine in patients with left ventricular systolic dysfunction and coronary artery disease [abstract 2637]. Eur Heart J 2004; 25 Suppl.: 451

    Article  Google Scholar 

  31. Savelieva I, Le Heuzey JY, Jern S, et al. Heart rate variability is significantly increased by ivabradine compared with amlodipine in patients with chronic stable angina: a prospective randomized double-blind controlled study [abstract 908-242]. J Am Coll Cardiol 2007; 49 Suppl. A: 9

    Google Scholar 

  32. Lombardi F. Clinical implications of present physiological understanding of HRV components. Card Electrophysiol Rev 2002; 6: 245–9

    Article  PubMed  Google Scholar 

  33. Babu S, Holgate ST, Gadzik F. Absence of respiratory effects in asthmatic subjects with the If inhibitor ivabradine, a novel anti-anginal agent [abstract]. Eur Resp J 2006; 28 Suppl.: 50

    Google Scholar 

  34. Borer J. Clinical efficacy and biological tolerability of the If inhibitor ivabradine in diabetic patients with chronic stable angina [abstract no P2096]. Eur Heart J 2006; 27 Suppl. 1: 329

    Google Scholar 

  35. European Society of Cardiology. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81

    Google Scholar 

Download references

Acknowledgements

Dr Tardif has received honoraria from Servier. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec, Canada, H1T 1C8

    Jean-Claude Tardif

  2. Université de Montréal, Montreal, Quebec, Canada

    Jean-Claude Tardif

Authors
  1. Jean-Claude Tardif
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Claude Tardif.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tardif, JC. Clinical Results of If Current Inhibition by Ivabradine. Drugs 67 (Suppl 2), 35–41 (2007). https://doi.org/10.2165/00003495-200767002-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767002-00005

Keywords

Search

Navigation